Evidence map›Paper›PMID 40736245›Full record

ArticleMicrobiology spectrum2025

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on

Elise Biquand, Sandra Khau, Delphine Fouquenet, Samanta Chouela Mbouwe, Floriane Costes, Lucile Drobecq, Adélaïde Chesnay, Guillaume Desoubeaux, Benoit Briard

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Elise Biquand *Centre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France.ORCID 0000-0001-9387-2550
Sandra Khau *Centre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France.ORCID 0009-0004-3348-6569
Delphine FouquenetCentre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France.ORCID 0009-0005-4179-7997
Samanta Chouela MbouweCentre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France.ORCID 0009-0000-4620-4146
Floriane CostesCentre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France.ORCID 0009-0005-9586-5959
Lucile DrobecqCentre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France.ORCID 0009-0007-8123-6304
Adélaïde ChesnayCentre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France.ORCID 0000-0001-6218-2442
Guillaume DesoubeauxCentre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France.ORCID 0000-0001-7945-9890
Benoit BriardCentre d'Étude des Pathologies Respiratoires, Inserm UMR1100, Université de Tours, Tours, France.ORCID 0000-0002-1496-9408

Funding

Association Vaincre la Mucoviscidose RF20220503069, RF20230503265
6 · The paper itself

Abstract

Fungal infection, especially allergic bronchopulmonary aspergillosis, is a leading cause of infection-associated morbidity and death in patients with cystic fibrosis. We have previously discovered that the new leading treatment in cystic fibrosis, CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor (ETI, Trikafta), drastically reduces the colonization and infection by

Indexed as

AminophenolsAspergillus fumigatusBenzodioxolesIndolesPyrazolesPyridinesQuinolinesAnimalsAspergillosisBiofilmsCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsMacrophagesMiceMice, Inbred C57BLAminophenolsBenzodioxolesCftr protein, mouseCystic Fibrosis Transmembrane Conductance RegulatorDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationIndolesPyrazolesPyridinesQuinolinesAspergillus fumigatuscftr modulatorscystic fibrosisElexakaftor/Tezacaftor/Ivacaftor

Identifiers

PMID40736245
PMCPMC12403852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.